SCHEMBL7968232

SCHEMBL7968232

Cc1ccc(OC[C@H]2CO2)c(C(=O)c2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 3/20 0.51
ALDH1A1 P00352 1/20 0.50
GLA P06280 1/20 0.50
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46
PTGDR2 Q9Y5Y4 2/20 0.46
SRC P12931 2/20 0.46
TGFBR1 P36897 2/20 0.46
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7968234 1.00 ABCB1 (0.51) ABCB1ALDH1A1GLATP53GAA
SCHEMBL7968230 1.00 ABCB1 (0.51) ABCB1ALDH1A1GLATP53GAA
SCHEMBL7754055 0.84 ALDH1A1 (0.54) ABCB1ALDH1A1GLATDP1
SCHEMBL11217801 0.83 ABCB1 (0.49) ABCB1ALDH1A1GLASRCTGFBR1
SCHEMBL10734017 0.82 ALDH1A1 (0.56) ALDH1A1GLATP53TDP1
SCHEMBL11483765 0.81 ALDH1A1 (0.51) ALDH1A1GLATP53NPSR1TDP1
SCHEMBL4221973 0.81 MAPT (0.47) ALDH1A1GLATP53GAANPSR1
SCHEMBL3897600 0.80 SRC (0.78) SRCTGFBR1
SCHEMBL7177104 0.80 ABCB1 (0.61) ABCB1TP53GAAPTGDR2SRC
SCHEMBL21668247 0.80 TDP1 (0.53) ALDH1A1GLATP53GAASRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6242450-B1 SUBSTITUTED PIPERIDINES ELI LILLY AND COMPANY 2001-06-05 US disclosed
WO-2000006082-A2 TREATMENT OF ANXIETY DISORDERS ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed
WO-2000006166-A1 5-HT1F ANTAGONISTS ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed
EP-0976746-A1 5-HT1F antagonists ELI LILLY AND COMPANY (US) 2000-02-02 EP disclosed
EP-0976747-A2 Use of 5HT-1F receptor antagonists for treating anxiety disorders ELI LILLY AND COMPANY (US) 2000-02-02 EP disclosed